MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'adt'. Sat, 03 Sep 2011 03:35:28 +0100 http://www.medworm.com/index.php?rid=4151792&cid=t_423568_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fwhen-doctors-are-paid-less-unnecessary-prescriptions-drop%2F2010.11.09 Take medical uncertainty. Add financial incentive to treat. Voila! Increased utilization. Now take away financial incentive to treat. Guess what you get? MedPageToday explains, in the case of hormone therapy for prostate cancer: Medicare accomplished what clinical guidelines and evidence-based medicine couldn’t: it reduced unnecessary use of androgen deprivation therapy (ADT) in prostate cancer. Inappropriate use decreased by almost 30% from 2003 to 2005, following enactment of the Medicare Modernization Act, which lowered physician reimbursement for ADT. Appropriate use of ADT did not change during the same time period, according to an article in the Nov. 4 issue of the New England Journal of Medicine. “Our findings suggest that reductions in reimbursement may influence the de... Better Health blogs http://www.medworm.com/rss/comments.php?id=4151792 Tue, 09 Nov 2010 19:00:48 +0100 4151792 http://www.medworm.com/index.php?rid=2786239&cid=t_423568_136_f&fid=35294&url=http%3A%2F%2Fwww.psa-rising.com%2Fblog%2F2009%2F09%2Fteleconference-estrogen-deficiency-side-effects-due-to-androgen-deprivation-therapy%2F Us TOO University Presents: Estrogen Deficiency Side Effects Due to Androgen Deprivation Therapy. This free webinar/teleconference with speaker Samir Taneja MD will take place Wednesday, September 23, 2009, at 8pm Eastern, 7pm Central, 6pm Mountain, 5pm Pacific. For more information and to RSVP today, go to: http://www.ustooevents.org/site/Survey?ACTION_REQUIRED=URI_ACTION_USER_REQUESTS&SURVEY_ID=2700 (Source: psa-rising.com/blog) psa-rising.com/blog blogs http://www.medworm.com/rss/comments.php?id=2786239 Thu, 10 Sep 2009 21:57:49 +0100 2786239 http://www.medworm.com/index.php?rid=2719939&cid=t_423568_136_f&fid=35294&url=http%3A%2F%2Fwww.psa-rising.com%2Fblog%2F2009%2F08%2Fdenosumab-in-men-receiving-androgen-deprivation-therapy-for-prostate-cancer%2F Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. Matthew R. Smith and an international team investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-{kappa}B ligand, on bone mineral density and fractures in men receiving androgen-deprivation therapy [...] (Source: psa-rising.com/blog) psa-rising.com/blog blogs http://www.medworm.com/rss/comments.php?id=2719939 Thu, 20 Aug 2009 12:48:46 +0100 2719939 http://www.medworm.com/index.php?rid=2067697&cid=t_423568_136_f&fid=35294&url=http%3A%2F%2Fwww.psa-rising.com%2Fblog%2F2008%2F12%2Fdegarelix-effect-compared-to-lupron%2F Below are a graph and a table of the effect of Ferring’s degarelix on testosterone compared with the effect of Lupron. On December 24th Ferring announced that FDA has approved degarelix for the treatment of hormonally sensitive advanced prostate cancer. The company has yet to announce a brand name for their product (which makes the online [...] (Source: psa-rising.com/blog) psa-rising.com/blog blogs http://www.medworm.com/rss/comments.php?id=2067697 Sun, 28 Dec 2008 07:11:51 +0100 2067697 http://www.medworm.com/index.php?rid=1129518&cid=t_423568_136_f&fid=36051&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FCancerCommentary%2F%7E3%2F210922900%2F This study demonstrates that the benefits of short-term hormonal therapy for men receiving radiation therapy for prostate cancer far outweigh the risks. While four months of hormonal therapy isn’t enough to cause significant side effects, we found that it can delay the development of bone metastasis by as many as eight years, which is very significant. So by taking a little bit of hormonal therapy early, patients may avoid having to take a lot of it later.” The study is published online January 2 in the Journal of Clinical Oncology. Find more details from American Society of Clinical Oncology. Share This (Source: Cancer Commentary) Cancer Commentary blogs http://www.medworm.com/rss/comments.php?id=1129518 Fri, 04 Jan 2008 05:06:23 +0100 1129518